In addition, all available treatments for advanced EGFR mutated NSCLC were considered in our study, thus a single threshold was impossible to represent decision maker’s WTP for QALYs gained and was not appropriate in all decision contexts (55). Here, EGFR is linked to non-small cell lung carcinoma.